Rev. 11-3/98

## DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

	(X) Original	( ) Supplemental ( ) Subs	titute ( )	PCT ( ) Design	
to my name; tha	t I verily believe that	I hereby declare that: my residence I am the original, first and sole invented below) of the subject matter when	, post office ad	dress and citizenship are a name is listed below) o	r an original, first and
Title:	COMBINE	PHARMACEUTICAL COMPOS	TION		
( ) the attached and with am ( ) the specification on  I hereby state the any amendment of acknowledge mangle defined in Title 3. I hereby claim prifor patent or investigated in the second of the second o	tion in International A  at I have reviewed a  att(s) referred to about  y duty to disclose to  7, Code of Federal  centor's certificate list	application No. PCT/ JP2005/00 application No. PCT/ JP2005/00 applicable).  Indication No. PCT/ JP2005/00 applicable).	ove-identified s  Il information k  nd §172 if this a	pecification, including the nown to me to be mater	e claims, as amended rial to patentability as
cou	NTRY	APPLICATION NO.	Da	ATE OF FILING	PRIORITY CLAIMED
COUI Jap		APPLICATION NO. 032329/2004		uary 9, 2004	1 11
					CLAIMED
					CLAIMED
					CLAIMED
hereby claim the ubject matter of the first paragraph d in Title 37, Co CT international	benefit under Title 3 each of the claims of of Title 35, United St	032329/2004  5, United States Code, §120 of any this application is not dislcosed in thates Code, §112, I acknowledge the tions, §1.56 which occurred betwee olication.	United States e prior United duty to disclose n the filing dat	application(s) listed below States application in the information material to pe of the prior application	claimed  claimed  w and, insofar as the manner provided by patentability as definant the national or
hereby claim the ubject matter of the first paragraph d in Title 37, Co CT international	benefit under Title 3 each of the claims of of Title 35, United St de of Federal Regula filing date of this app	5, United States Code, §120 of any this application is not dislcosed in thates Code, §112, I acknowledge the tions, §1.56 which occurred between	United States e prior United duty to disclose n the filing dat	application(s) listed below States application in the information material to p	w and, insofar as the manner provided by patentability as definant the national or
hereby claim the ubject matter of the first paragraph d in Title 37, Co CT international	benefit under Title 3 each of the claims of of Title 35, United St de of Federal Regula filing date of this app	032329/2004  5, United States Code, §120 of any this application is not dislcosed in thates Code, §112, I acknowledge the tions, §1.56 which occurred betwee olication.	United States e prior United duty to disclose n the filing dat	application(s) listed below States application in the information material to pe of the prior application	w and, insofar as the manner provided by patentability as definant the national or

And I hereby appoint John T. Miller, Reg. No. 21,120; Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils E. Pedersen, Reg. No. 33,145 and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from \_\_\_\_\_\_ as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

WENDEROTH, LIND & PONACK, L.L.P. 2033 K Street, N.W., Suite 800 Washington, DC 20006

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P. Area Code (202) 721-8200

Direct Facsimile Messages to: Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME KANAZAWA	FIRST GIVEN NAME Hashime	SECOND GIVEN NAME		
Residence &	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP		
Citizenship	Tokyo	Japan	Japan		
Post Office Address	ADDRESS C/O ASKA Pharmaceutical Co., Ltd., Nishitokyo Research Center, 4-3, Sakaecho 3-chome, Hamura-shi, Tokyo 205-8501 Japan				
Full Name of	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME		
Second Inventor	ISHITANI	Kouki			
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP		
	Tokyo	Japan	Japan		
Post Office Address	ADDRESS C/O ASKA Pharmaceutical Co., Ltd., Nishitokyo Research Center, 4-3, Sakaecho 3-chome, Hamura-shi, Tokyo 205-8501 Japan				
Full Name of	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME		
	FAMILY NAME SUDO	FIRST GIVEN NAME Katsuichi	SECOND GIVEN NAME		
			SECOND GIVEN NAME COUNTRY OF CITIZENSHIP		
Third Inventor	SUDO	Katsuichi			
Third Inventor  Residence & Citizenship  Post Office	SUDO  CITY  Tokyo  ADDRESS C/O ASKA Pharmaceuti	Katsuichi STATE OR COUNTRY	COUNTRY OF CITIZENSHIP  Japan  TATE OR COUNTRY  Research Center,		
Third Inventor  Residence &	SUDO  CITY  Tokyo  ADDRESS C/O ASKA Pharmaceuti	Katsuichi  STATE OR COUNTRY  Japan  CITY S  Cal Co., Ltd., Nishitokyo	COUNTRY OF CITIZENSHIP  Japan  TATE OR COUNTRY  Research Center,		
Third Inventor  Residence & Citizenship  Post Office Address  Full Name of	SUDO  CITY  Tokyo  ADDRESS C/O ASKA Pharmaceuti 4-3, Sakaecho 3-cho	Katsuichi  STATE OR COUNTRY  Japan  CITY S  Cal Co., Ltd., Nishitokyo ome, Hamura-shi, Tokyo 205	COUNTRY OF CITIZENSHIP  Japan  TATE OR COUNTRY  Research Center,  -8501 Japan		
Third Inventor  Residence & Citizenship  Post Office Address	SUDO  CITY Tokyo  ADDRESS C/O ASKA Pharmaceuti 4-3, Sakaecho 3-cho  FAMILY NAME	Katsuichi  STATE OR COUNTRY  Japan  CITY S  Cal Co., Ltd., Nishitokyo Ome, Hamura-shi, Tokyo 205	COUNTRY OF CITIZENSHIP  Japan  TATE OR COUNTRY  Research Center,  -8501 Japan		
Residence & Citizenship  Post Office Address  Full Name of Fourth Inventor	SUDO  CITY Tokyo  ADDRESS C/O ASKA Pharmaceuti 4-3, Sakaecho 3-cho  FAMILY NAME TANIMORI	Katsuichi  STATE OR COUNTRY  Japan  CITY S  Cal Co., Ltd., Nishitokyo  DIME, Hamura-shi, Tokyo 205  FIRST GIVEN NAME  Naoto	COUNTRY OF CITIZENSHIP  Japan  TATE OR COUNTRY  Research Center,  -8501 Japan  SECOND GIVEN NAME		

Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
Residence & Citizenship	СІТҮ	STATE OR COUNTRY	COUNTRY OF C	ITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GI	VEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF C	ITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Seventh Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GI	VEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP	
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Composition   Composition	1st Inventor M. Language	(Hashime KANAZAWA	Date	28th July 2006			
Ath Inventor Nacto Tanimori (Naoto TANIMORI)  Date 28th July 2006  Sth Inventor Date  The above application may be more particularly identified as follows:  U.S. Applicant Reference Number Atty Docket No	2nd Inventor			0			
Ath Inventor Nacto Tanimori (Naoto TANIMORI)  Date 28th July 2006  Sth Inventor Date  The above application may be more particularly identified as follows:  U.S. Applicant Reference Number Atty Docket No.	3rd Inventor hat suichi Sude			4			
Sth Inventor Date	· · · · · · · · · · · · · · · · · · ·			•			
The above application may be more particularly identified as follows:  U.S. Application Serial No Filing Date  Applicant Reference Number Atty Docket No				•			
The above application may be more particularly identified as follows:  U.S. Application Serial No Filing Date  Applicant Reference Number Atty Docket No	6th Inventor		Date				
U.S. Application Serial No Filing Date  Applicant Reference Number Atty Docket No	7th Inventor		Date				
Applicant Reference Number Atty Docket No							
Title of Invention COMBINED PHARMACEUTICAL COMPOSITION			)				
	Title of Invention COMBINED PHARMACEUTI	CAL COMPOSITION					